Medical AI Alliance
← Company Index
Biotech & Drug DiscoveryKOSDAQ 3480801 approvals5 trials

Quratis Inc.

Official website

Founded in 2016 and KOSDAQ-listed since 2023, Quratis develops tuberculosis, schistosomiasis, and COVID-19 vaccines and runs a CDMO plant.

As of 2026-10-11, Quratis Inc. has 1 Korean MFDS drug approval, 7 PubMed-indexed papers on record (counted by the MAA Company Index from its own matching of public databases).

Price

Change

Market cap

Business overview

Source: DART corporate disclosure

Quratis was founded in 2016 and listed on KOSDAQ in 2023 as a vaccine developer. It develops tuberculosis vaccine QTP101, schistosomiasis vaccine QTP105, and mRNA COVID-19 vaccine QTP104, using recombinant protein and repRNA platforms with the GLA-SE adjuvant. Its Osong plant makes 50 million vials yearly, backed by deals with IDRI, HDT Bio, PAI Life Sciences, and China's Lukang Pharmaceutical.

Products & technology

  • QTP101Tuberculosis vaccine for BCG-vaccinated adults/adolescents and adults aged 55-74
  • QTP105Schistosomiasis vaccine
  • QTP104Next-generation mRNA COVID-19 vaccine

Regulatory approvals

data.go.kr

1 Korean MFDS drug approvals · 2022

  • MFDS drugQuaC inj.2022-01-12
    Drug · Prescription · Notification202200217

Clinical trials

data.go.kr

5 MFDS clinical trial authorisations · 2017–2024 (Phase 1 3 · Phase 2b/3 1 · Phase 2 1)

  • Phase 1QTP1012024-03-14

    7 trial sites

  • Phase 2b/3QTP1012022-07-21

    5 trial sites

  • Phase 1QTP1042021-07-19

    5 trial sites

  • Phase 1QTP1012018-12-11

    1 trial site

  • Phase 2QTP1012017-12-19

    3 trial sites

Global clinical trials

ClinicalTrials.gov · sponsor-matched

R&D and key agreements

Source: DART corporate disclosure

QTP101 · 결핵 예방 · 임상 2b/3상 (국내 IND 승인, 필리핀 PFDA 신청) · Completed Phase 1 in the US, Phase 1b/2a in South Africa, and Phase 2a (adult)/Phase 1 (adolescent) trials in Korea; IRB approvals obtained from 5 Korean institutions between May 27 and Sep 25, 2024 for the multinational Phase 2b/3 trial

QTP105 · 주혈흡충증 예방 · 임상 1b상 · Licensed from PAI Life Sciences

QTP104 · 코로나19 예방 · 임상 1상 종료 · Co-developed with HDT Bio

Key disclosures

KRX KIND via OpenDART
Show 10 more events

Publications

PubMed · affiliation-matched

Patents

KIPRIS · applicant-matched
Show 41 more patents

AI reads

MAA server logs · IP-verified
33
Times AI engines pulled Quratis Inc.'s records

Pulled records become part of each AI's index and keep feeding its answers. When an AI cites from that index, nothing reaches our server — so actual citations are uncounted here and exceed this number.

1
Fetched fresh mid-answer

Times an AI needed something not yet in its index and fetched this page fresh while answering. Citations served from the index leave no trace here.

32
Index crawls

Collected as raw material for future answers.

0
Direct AI-tool queries (MCP)

Queries from users who connected this index to their own AI.

10
live 1
Last 7 days
27
live 1
Last 30 days
33
live 1
All time
  • OpenAIChatGPT-Userlive1
  • OpenAIOAI-SearchBot25
  • GoogleGoogleOther2
  • PerplexityPerplexityBot2
  • AnthropicClaudeBot2
  • MicrosoftBingbot1

Measured since Aug 27, 2026 · 5 AI engines · last read Oct 10, 2026

User-agent strings can be forged, so we do not count them at face value. We count only requests matched against vendor-published IP ranges, or confirmed by forward-verified reverse DNS. MCP queries are actual calls to this index's tool endpoint.

Connect this index to your AI tool →

Connect this company index directly to your AI

Connect it to ChatGPT or Claude, and your AI queries the full record — profiles, financials, stock data, regulatory approvals, clinical trials, publications and patents — for Quratis Inc. and every listed Korean medical, bio and AI company.

How to connect (MCP)
Not yet compiled: business overview. Send us materials and we will add them

Companies in the same categoryBiotech & Drug Discovery

AHNLAB,INC.100

KOSDAQ-listed integrated security company behind the V3 antivirus and AhnLab TrusGuard and XDR solutions.

Inventage Lab Inc.100

Drug delivery system company behind the long-acting injectable platform IVL-DrugFluidic and the LNP delivery platform IVL-GeneFluidic.

ORGANOIDSCIENCES LTD.100

Organoid-based biotech founded 2018, KOSDAQ-listed 2025, developing the ATORM-C regenerative therapeutic and ODISEI evaluation solution.

Eone Diagnomics Genome Center Co., Ltd.85

EDGC, a Korea-US joint venture of Eone Medical Foundation and Diagnomics, offers the NIPT service NICE and liquid biopsy OncoCatch.

SK Chemicals Co., Ltd.85

A diversified SK group company operating eco-friendly chemical materials alongside pharmaceutical products like Joins and vaccines through subsidiary SK Bioscience.

CG Invites Co., Ltd.85

Genomics and drug developer behind the osteoarthritis drug Acelex and the AI-driven healthcare platform Invites Loop.

Y-Biologics, Inc85

KOSDAQ-listed antibody biotech developing the next-generation immuno-oncology candidate Multi-AbKine on its fully human antibody library Ymax®-ABL.

GC Corp.85

A holding company overseeing 54 affiliates including its main biopharmaceutical subsidiary GC, with no direct product manufacturing of its own.

Prestige BioPharma Limited85

Founded in 2015 and listed on KOSPI in 2021, Prestige BioPharma develops antibody biosimilars and novel antibody drugs including Tuznue.

GENEMATRIX INC.85

KOSDAQ-listed biotech company developing molecular diagnostics with proprietary C-Tag technology and the NeoPlex product line.

SillaJen, Inc.85

SillaJen, Inc., founded in 2006 and listed on KOSDAQ in 2016, develops the oncolytic virus immunotherapy Pexa-Vec.

SK Bioscience Co.,Ltd84

A vaccine specialist developing in-house products such as SKYCellflu and SKYZoster while also serving as CDMO for AstraZeneca and Novavax.

Sources and updates

Counts on this page are not company-reported figures. MAA matched records from DART, the Korean MFDS, the US FDA, ClinicalTrials.gov, PubMed and KIPRIS to this company itself, by business registration number or registered name, never by name similarity. They may differ from figures the company publishes.

Company basics
Korea Exchange · DART
Business content
Compiled from disclosure filings
Approvals & clinical trials
Korean MFDS (data.go.kr) · US FDA openFDA — updated weekly
Key disclosures
KRX KIND via OpenDART exchange filings — updated daily
Global clinical trials
ClinicalTrials.gov (US NIH) — sponsor-matched, updated weekly
Financials
DART corporate disclosure filings — annual
Publications
PubMed (US National Library of Medicine) — affiliation-matched, updated daily
Patents
KIPRIS (Korea Institute of Patent Information) — applicant-matched, updated monthly
AI reads
Our server logs, IP-verified every 6 hours
AI visibility
Measured 2026-10-01

This page is compiled from public sources without the company's involvement. If anything is inaccurate or incomplete, please let us know. Materials provided by the company are labelled as such.

Request a correction or addition